Peptide · Agonist of gonadotropin-releasing hormone receptor (GNRHR) · developed by Abbvie Endocrine
ApprovedFDA, Apr 1985
1Registered trials
What is Leuprolide?
Leuprolide is a synthetic nonapeptide analogue of gonadotropin-releasing hormone that binds GnRH receptors. Continuous administration desensitizes pituitary GnRH receptors, reducing FSH and LH secretion and suppressing testicular and ovarian steroid production. It is studied in early breast cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Eligard, Fensolvi, Lupron Depot, Vabrinty
Drug type
Peptide
Targets
gonadotropin-releasing hormone receptor (GNRHR)
Mechanism
Agonist of gonadotropin-releasing hormone receptor (GNRHR)
Pathways
pituitary gonadotropin (FSH and LH) secretion, testicular and ovarian steroidogenesis
Approved as Eligard, Fensolvi, Lupron Depot (April 9, 1985), NDA019010 · FDA label
✅ FDA-approved uses
Advanced prostate cancer (Vabrinty)
Advanced prostate cancer (Eligard)
Advanced prostate cancer (Lupron Depot)
Central precocious puberty (Fensolvi)
From the indications section of the FDA label (version of Apr 30, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.